Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 2 Issue 3, March 2021

Advancing Cancer Therapy

In this issue, we are launching a Series on Cancer Therapy comprising commissioned Reviews and Perspectives that highlight emerging concepts, recent advances and the challenges ahead in cancer therapy, and a selection of primary research articles on this topic published in Nature Cancer.

See our March Editorial, as well as the Review articles by Esposito et al. and by Mukhopadhyay et al.

Image: Alamy. Cover Design: Allen Beattie.

Editorial

  • Cancer therapies have evolved considerably in recent decades, substantially improving the quality of life and survival of patients with cancer. In this issue, we launch our Series on Cancer Therapy, exploring current paradigms and recent advances and challenges in this field, through specially commissioned articles.

    Editorial

    Advertisement

Top of page ⤴

Comment & Opinion

  • Cancer research has undergone transformational changes over the past several decades. On the occasion of the 20th anniversary of the establishment of the NCI Center for Cancer Research, we highlight some elements that enable successful institutional approaches to solving the most pressing problems in cancer research.

    • William Dahut
    • Glenn Merlino
    • Tom Misteli
    Comment
Top of page ⤴

News & Views

  • Shedding light on the mechanisms that underlie a durable response to immunotherapy, a recent study evaluating long-term survivors of melanoma treated with immunotherapy finds that tumor-associated T cell clonotypes are sustained over years and persist as expanded, cytokine IFN-γ–expressing resident memory T cells in the skin, with effector memory counterparts in the blood.

    • Anusha-Preethi Ganesan
    • Christian H. H. Ottensmeier
    News & Views
  • Pharmacogenomic drug screening provides a promising platform for the discovery of anti-cancer drugs, in combination with biomarkers and mechanisms that confer therapeutic response. A study now pinpoints the mechanisms of sensitivity to dasatinib in T-ALL leukemia, identifying a T cell–differentiation switch that determines sensitivity to distinct drug modalities.

    • Anders Jacobsen Skanderup
    • Ramanuj DasGupta
    News & Views
Top of page ⤴

Reviews

Top of page ⤴

Research

Top of page ⤴

Search

Quick links